2025.06.18 (수)

  • 맑음속초23.7℃
  • 맑음18.8℃
  • 맑음철원18.3℃
  • 맑음동두천19.4℃
  • 맑음파주19.5℃
  • 맑음대관령14.5℃
  • 맑음춘천18.8℃
  • 안개백령도14.4℃
  • 맑음북강릉21.9℃
  • 맑음강릉23.3℃
  • 구름많음동해21.7℃
  • 맑음서울22.3℃
  • 흐림인천20.6℃
  • 맑음원주21.8℃
  • 구름조금울릉도21.8℃
  • 구름많음수원20.9℃
  • 구름많음영월18.5℃
  • 구름조금충주21.7℃
  • 흐림서산19.2℃
  • 구름많음울진23.0℃
  • 맑음청주23.1℃
  • 맑음대전22.2℃
  • 맑음추풍령20.2℃
  • 구름많음안동22.0℃
  • 구름많음상주23.2℃
  • 구름많음포항23.6℃
  • 맑음군산20.3℃
  • 구름조금대구22.7℃
  • 맑음전주21.7℃
  • 구름많음울산20.0℃
  • 구름많음창원21.8℃
  • 맑음광주21.4℃
  • 안개부산20.7℃
  • 구름많음통영19.8℃
  • 맑음목포20.0℃
  • 구름조금여수20.7℃
  • 맑음흑산도19.2℃
  • 맑음완도19.6℃
  • 맑음고창20.3℃
  • 맑음순천19.4℃
  • 맑음홍성(예)20.7℃
  • 맑음21.8℃
  • 구름조금제주21.1℃
  • 구름조금고산19.9℃
  • 구름많음성산19.0℃
  • 구름조금서귀포21.1℃
  • 구름조금진주20.8℃
  • 흐림강화19.2℃
  • 맑음양평21.1℃
  • 맑음이천21.4℃
  • 맑음인제17.7℃
  • 맑음홍천19.7℃
  • 흐림태백17.1℃
  • 맑음정선군17.1℃
  • 맑음제천18.9℃
  • 맑음보은20.7℃
  • 맑음천안20.1℃
  • 구름많음보령20.3℃
  • 맑음부여20.5℃
  • 맑음금산21.5℃
  • 맑음21.3℃
  • 맑음부안20.0℃
  • 맑음임실19.7℃
  • 맑음정읍20.6℃
  • 맑음남원20.5℃
  • 맑음장수18.7℃
  • 맑음고창군19.2℃
  • 맑음영광군19.7℃
  • 구름많음김해시21.1℃
  • 맑음순창군20.7℃
  • 구름조금북창원23.1℃
  • 구름많음양산시21.8℃
  • 맑음보성군20.7℃
  • 맑음강진군19.9℃
  • 맑음장흥19.4℃
  • 맑음해남18.6℃
  • 맑음고흥18.0℃
  • 구름조금의령군20.4℃
  • 맑음함양군19.8℃
  • 맑음광양시20.9℃
  • 구름많음진도군17.5℃
  • 흐림봉화19.1℃
  • 흐림영주20.9℃
  • 구름조금문경20.5℃
  • 구름조금청송군19.8℃
  • 구름조금영덕21.5℃
  • 구름조금의성22.3℃
  • 맑음구미23.5℃
  • 구름조금영천21.7℃
  • 구름조금경주시21.8℃
  • 맑음거창19.7℃
  • 맑음합천22.0℃
  • 구름조금밀양22.4℃
  • 맑음산청20.9℃
  • 구름많음거제20.6℃
  • 구름많음남해19.6℃
  • 안개21.2℃
기상청 제공
Shoppy 로고
GI CELL Enters Agreement with Optieum Biotechnologies
  • 해당된 기사를 공유합니다

GI CELL Enters Agreement with Optieum Biotechnologies

GI CELL, Inc. announced that it has entered into a research license and option agreement with Optieum Biotechnologies, Inc. (Japan).

Under the agreement, Optieum Biotechnologies will provide GI CELL with scFv antibodies directed against hematological tumor targets generated through Optieum Biotechnologies’ Eumbody System™. GI CELL will carry out feasibility studies and be responsible for further development and commercialization of the CAR-NK cell products if the company exercises an option. For each option exercised, Optieum Biotechnologies will be entitled to an option-exercise fee, development and commercial milestone payments, as well as single-digit royalties on sales.

“We are pleased to enter this collaboration with Optieum Biotechnologies as we continue unlocking the full potential of our NKPURE Expander® platform,” said Dr. Chun Pyo Hong, CEO of GI CELL. “We look forward to evaluating the scFv antibodies from Optieum Biotechnologies’ discovery platform, which have the potential to accelerate the development of our novel CAR-NK cells.”

“We have been dedicated to expanding the toolbox to enable immune cell-based therapies in cancer treatment, through our proprietary Eumbody System™. Optieum Biotechnologies’ strength in discovery of functional and improved scFvs in conjunction with GI CELL’s expertise in NK cell engineering and manufacturing may lead to a generation of promising cellular immunotherapy for unmet medical needs,” said Shun Nishioka, CEO of Optieum Biotechnologies.

About GI CELL

GI CELL is a biotechnology company that drives research and development of novel immune cell-based therapies with innovative technologies. Using its proprietary Immune CellPURE Expander® platform for highly potent NK and T cell development, GI CELL has integrated its ancillary material screening and cell expansion technologies to streamline the entire cell product development process. The Company is advancing its allogenic NK cell therapies to transform the treatment paradigm for patients with hematological malignancies and solid tumors. GI CELL has multiple NK cell product candidates in IND-enabling and preclinical development.

About Optieum Biotechnologies

Optieum Biotechnologies is a biotechnology company with a platform engine to elicit functional and improved scFvs for CAR-T cell and CAR-NK therapies with superior anti-tumor toxicity and persistence. Optieum Biotechnologies’ scFv generation platform, Eumbody System, enables to acquire the scFv from the CAR-T cell’s functionality perspective rather than conventional binding affinity approach. The company is advancing multiple CAR-T cell product candidates targeting hematological malignancies and solid tumors which demonstrate significantly improved anti-tumor toxicity, proliferation capacity and mitigated antigen depletion.

언론연락처: GI CELL, Inc. Heehyoung Lee, PhD EVP, BD and Corporate Strategy or

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.




포토

 
모바일 버전으로 보기